Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chad E Beyer

Showing results (31-40 of 35) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 35 results.
Journal of Medicinal Chemistry|October 24, 2007
Discovery of N1-(6-chloroimidazo[2,1-b][1,3]thiazole-5-sulfonyl)tryptamine as a potent, selective, and orally active 5-HT(6) receptor agonistDerek C Cole, Joseph R Stock, William J Lennox, et al.
Journal of Medicinal Chemistry|September 2, 2009
Synthesis, potency, and in vivo evaluation of 2-piperazin-1-ylquinoline analogues as dual serotonin reuptake inhibitors and serotonin 5-HT1A receptor antagonistsDahui Zhou, Gary P Stack, Jennifer Lo, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 30, 2008
ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activitiesFeng Liu, Steve Grauer, Cody Kelley, et al.
The International Journal of Neuropsychopharmacology|January 6, 2010
Preclinical characterization of BRL 44408: antidepressant- and analgesic-like activity through selective alpha2A-adrenoceptor antagonismJason M Dwyer, Brian J Platt, Stacey J Sukoff Rizzo, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 16, 2009
WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activityJulie A Brennan, Radka Graf, Steven M Grauer, et al.
Pageof 4

Showing results (31-40 of 35) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 35 results.
Journal of Medicinal Chemistry|October 24, 2007
Discovery of N1-(6-chloroimidazo[2,1-b][1,3]thiazole-5-sulfonyl)tryptamine as a potent, selective, and orally active 5-HT(6) receptor agonistDerek C Cole, Joseph R Stock, William J Lennox, et al.
Journal of Medicinal Chemistry|September 2, 2009
Synthesis, potency, and in vivo evaluation of 2-piperazin-1-ylquinoline analogues as dual serotonin reuptake inhibitors and serotonin 5-HT1A receptor antagonistsDahui Zhou, Gary P Stack, Jennifer Lo, et al.
The Journal of Pharmacology and Experimental Therapeutics|August 30, 2008
ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activitiesFeng Liu, Steve Grauer, Cody Kelley, et al.
The International Journal of Neuropsychopharmacology|January 6, 2010
Preclinical characterization of BRL 44408: antidepressant- and analgesic-like activity through selective alpha2A-adrenoceptor antagonismJason M Dwyer, Brian J Platt, Stacey J Sukoff Rizzo, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 16, 2009
WS-50030 [7-{4-[3-(1H-inden-3-yl)propyl]piperazin-1-yl}-1,3-benzoxazol-2(3H)-one]: a novel dopamine D2 receptor partial agonist/serotonin reuptake inhibitor with preclinical antipsychotic-like and antidepressant-like activityJulie A Brennan, Radka Graf, Steven M Grauer, et al.
Pageof 4